van Groningen J J, Bloemers H P, Swart G W
Department of Biochemistry, University of Nijmegen, The Netherlands.
Cancer Res. 1995 Dec 15;55(24):6237-43.
The differential display technique was used to identify mRNAs differentially expressed in human melanoma cell lines with different metastatic capacity. We report the isolation of nine different clones, of which four were uniquely expressed in the highly metastatic human melanoma cell line MV3, whereas the other five clones were uniquely expressed in the poorly metastatic human melanoma cell line 530. The differences in expression identified by differential mRNA display were confirmed by Northern blot analyses. DNA sequencing followed by computer search analyses indicated that of the nine differentially expressed clones, five represented novel gene products. The other four were histocompatibility antigen HLA-DR, laminin B2, melanoma inhibitory activity (MIA), and tissue inhibitor of metalloproteinases 3. MIA was also identified in RNA from human melanoma metastasis lesions in a comparison by differential display with pooled human nevi. Northern blot analysis confirmed MIA mRNA expression in nonmetastasizing melanoma cell lines and in melanoma metastasis lesions, while expression was absent in highly metastasizing cell lines and pretumor stages. In the 11 metastasis lesions examined, MIA mRNA expression was apparently inversely correlated with pigmentation.
采用差异显示技术来鉴定在具有不同转移能力的人黑色素瘤细胞系中差异表达的mRNA。我们报告分离出9个不同的克隆,其中4个在高转移性人黑色素瘤细胞系MV3中独特表达,而其他5个克隆在低转移性人黑色素瘤细胞系530中独特表达。通过差异mRNA显示鉴定出的表达差异经Northern印迹分析得以证实。DNA测序随后进行计算机搜索分析表明,在这9个差异表达的克隆中,5个代表新的基因产物。另外4个是组织相容性抗原HLA - DR、层粘连蛋白B2、黑色素瘤抑制活性(MIA)和金属蛋白酶组织抑制剂3。通过与汇集的人痣进行差异显示比较,在人黑色素瘤转移病灶的RNA中也鉴定出了MIA。Northern印迹分析证实MIA mRNA在非转移性黑色素瘤细胞系和黑色素瘤转移病灶中表达,而在高转移性细胞系和肿瘤前期阶段则无表达。在所检测的11个转移病灶中,MIA mRNA表达显然与色素沉着呈负相关。